Santamaria Francesca, Ziello Carla, Lorello Paola, Bouchè Cristina, Borrelli Melissa
Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
Front Pediatr. 2022 Jul 19;10:896865. doi: 10.3389/fped.2022.896865. eCollection 2022.
Tiotropium bromide is the only long-acting muscarinic antagonist (LAMA) approved for treatment of patients aged ≥6 years old who have symptoms of uncontrolled asthma. Results from several clinical trials have found that once-daily inhaled tiotropium bromide is safe and efficacious in 6- to 17-year-olds with symptomatic asthma despite treatment with inhaled corticosteroids, with or without other medications. There are still few available studies investigating the impact of tiotropium bromide treatment in preschool children with suboptimal control. In this narrative review, we summarize the pharmacological effects of the LAMA tiotropium bromide, provide an overview about current asthma studies at different pediatric ages, and describe future research needs.
噻托溴铵是唯一被批准用于治疗≥6岁有未控制哮喘症状患者的长效毒蕈碱拮抗剂（LAMA）。多项临床试验结果表明，对于6至17岁有症状的哮喘患者，无论是否使用吸入性糖皮质激素及其他药物，每日一次吸入噻托溴铵都是安全有效的。目前关于噻托溴铵治疗对控制不佳的学龄前儿童影响的研究仍然很少。在这篇叙述性综述中，我们总结了LAMA噻托溴铵的药理作用，概述了当前不同儿童年龄阶段的哮喘研究情况，并描述了未来的研究需求。
